Refractory Anemia With Excess Of Blasts
Watchlist
Retrieved
2021-01-18
Source
Trials
—
Genes
TET2,
FANCB,
CD34,
RUNX1,
CCR7,
MECOM,
KMT2A,
EPO,
GATA2,
HPSE2,
ACSL5,
SF3B1,
ACSL6,
AKAP12,
DLK1,
CIP2A,
IGHV1-12,
ACHE,
NSD1,
VEGFA,
DERL1,
ATAD1,
ASXL1,
ILDR1,
MIR29B1,
MIR29B2,
VIM2P,
MOGS,
SRSF2,
U2AF1
TET2,
FANCB,
CD34,
RUNX1,
CCR7,
MECOM,
KMT2A,
EPO,
GATA2,
HPSE2,
ACSL5,
SF3B1,
ACSL6,
AKAP12,
DLK1,
CIP2A,
IGHV1-12,
ACHE,
NSD1,
VEGFA,
DERL1,
ATAD1,
ASXL1,
ILDR1,
MIR29B1,
MIR29B2,
VIM2P,
MOGS,
SRSF2,
U2AF1,
THY1,
BCL2,
BCR,
CBL,
CDKN2B,
CHEK1,
CSF3,
ETV6,
FLT3,
HLA-DRB1,
ITGA2B,
MCL1,
NCAM1,
NRAS,
RARS1,
BCHE,
SPN,
THPO,
U2AF1L5
Drugs
—
Registered!
Refractory anemia with excess of blasts (RAEB) is a type of myelodysplastic syndrome with a marrow blast percentage of 5% to 19%.
In MeSH, "Smoldering leukemia" is classified under RAEB.